A real-world study on implementation of bevacizumab in a cohort of HER2-negative metastatic breast cancer patients: A study of the Southeast Netherlands Breast Cancer Consortium

Bevacizumab was prescribed less frequently than expected, offered to a selected population and frequently outside guideline recommendations. Early field research on the implementation, use and effectiveness of new drugs in daily practice is necessary to guarantee effective implementation of these drugs.